EXEL News and Press, Exelixis Inc. From 11/02/21

Exelixis (NASDAQ:EXEL): Q3 Non-GAAP EPS of $0.20 beats by $0.02; GAAP EPS of $0.12 misses by $0.06. Revenue of $328.4M (+42.1% Y/Y) misses by $28.66M. Shares -6%. Press Release FY21 outlook: Revenue $1.3B-$1.35B vs. $1.39B consensus. Cash and investments $1.8B Net product revenues $1,050...

- Total Revenues of $328.4 Million, Cabozantinib Franchise Revenues of $263.1 Million - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.20 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) today repo...

With stocks hitting new highs again today, it's always nice to find a stock that isn't overvalued. Exelixis, Inc. (EXEL) is one such stock. The company's lead molecule, cabozantinib, offers treatment for numerous indications, which makes this an intriguing pick. Investors looking for value st...

Yesterday, Cortexyme (NASDAQ: CRTX) , a clinical-stage biotech, saw its shares drop by a whopping 76%. The drugmaker's stock crumbled after the company announced that the experimental Alzheimer's disease therapy, atuzaginstat, missed the co-primary endpoints of its phase 2/3 GAIN tr...

The U.S economy could grow significantly in the near term, driven by potential multi-trillion-dollar government infrastructure spending and a continuing low-interest-rate environment. Therefore, we think the shares of Steel Dynamics (STLD), Exelixis (EXEL), and Conn’s, Inc. (CONN), whi...

In addition to playing a crucial role in the fight against COVID-19, the biotech industry is focusing increasingly on developing solutions to treat other critical ailments. And given the industry’s solid growth prospects, we think it could be wise to bet on quality biotech stocks QIAGE...

– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021 after the markets close. At 5:00 p.m. EDT / ...

– STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform – Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered ...

– Robust preclinical data support Exelixis’ clinical development of XL114, with phase 1 trial in Non-Hodgkin’s lymphoma expected to begin in the coming months – – Exelixis will make an option exercise payment of $10 million to Aurigene ȁ...

Drug development company Aeterna Zentaris (AEZS), specialized in oncology and endocrine, has made significant advancements in areas of unmet medical needs. But since its therapeutic and diagnostic products are still in their clinical and preclinical development stages, commercialization could...